Payment overview · 2025
General Payments
$854.19
44 reported records · 18 companies
Healthcare provider profile · identity verified
Jason Anthony Ham, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · FORT PAYNE, AL · NPI 1245560796
Verified facts
What the public records show
CMS Open Payments records show Jason Anthony Ham, M.D. received $854.19 in general payments during 2025 across 44 reported records.
Novo Nordisk Inc accounted for 17.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Mounjaro, Nurtec Odt, Ozempic, Rybelsus.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 190 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 144 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 144 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 413 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 104 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 325 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 246 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Nurtec Odt by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $153.14 | 17.9% | 8 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $99.68 | 11.7% | 5 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $83.67 | 9.8% | 4 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $72.47 | 8.5% | 3 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $68.72 | 8.1% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $60.48 | 7.1% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $49.37 | 5.8% | 3 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $43.64 | 5.1% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $35.93 | 4.2% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $31.67 | 3.7% | 2 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $30.96 | 3.6% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $22.65 | 2.6% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $19.78 | 2.3% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $19.64 | 2.3% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $18.06 | 2.1% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $15.77 | 1.9% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.93 | 1.8% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $13.63 | 1.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $854.19 | 44 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $111.88 | 6 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $94.60 | 5 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $83.67 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $80.63 | 4 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $72.47 | 3 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $68.72 | 3 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $60.48 | 4 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $50.72 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $49.37 | 3 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $43.64 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $35.93 | 2 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $30.96 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $29.65 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $22.65 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $20.85 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $19.78 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $19.72 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $19.64 | 1 | 2025 |
Source payment records
|
|||||
| General - Pain Management Normalized: general pain management |
Device | Boston Scientific Corporation | $18.06 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $15.77 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.93 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $13.63 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 246 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 144 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 413 | exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 325 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 44 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
23 | 20 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
190 | 40 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
53 | 12 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
144 | 33 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
144 | 33 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
413 | 74 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
104 | 18 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
325 | 68 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
44 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
246 | 57 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
62 | 60 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 2065 | 276 |
| Gabapentin | Gabapentin | 1468 | 241 |
| Pantoprazole Sodium | Pantoprazole Sodium | 1017 | 267 |
| Levothyroxine Sodium | Levothyroxine Sodium | 943 | 225 |
| Montelukast Sodium | Montelukast Sodium | 911 | 267 |
| Atorvastatin Calcium | Atorvastatin Calcium | 852 | 228 |
| Alprazolam | Alprazolam | 846 | 114 |
| Omeprazole | Omeprazole | 801 | 192 |
| Amlodipine Besylate | Amlodipine Besylate | 730 | 189 |
| Lisinopril | Lisinopril | 729 | 206 |
| Clonazepam | Clonazepam | 635 | 90 |
| Metformin Hcl | Metformin Hcl | 627 | 156 |
| Tramadol Hcl | Tramadol Hcl | 603 | 123 |
| Furosemide | Furosemide | 596 | 177 |
| Trazodone Hcl | Trazodone Hcl | 564 | 139 |
| Meloxicam | Meloxicam | 558 | 174 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 552 | 158 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 540 | 72 |
| Tizanidine Hcl | Tizanidine Hcl | 513 | 141 |
| Losartan Potassium | Losartan Potassium | 505 | 146 |
| Fluticasone Propionate | Fluticasone Propionate | 462 | 129 |
| Metoprolol Succinate | Metoprolol Succinate | 423 | 119 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 423 | 129 |
| Mounjaro | Tirzepatide | 413 | 74 |
| Pregabalin | Pregabalin | 413 | 69 |
| Lorazepam | Lorazepam | 392 | 59 |
| Potassium Chloride | Potassium Chloride | 392 | 102 |
| Diclofenac Sodium | Diclofenac Sodium | 389 | 118 |
| Sertraline Hcl | Sertraline Hcl | 383 | 104 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 372 | 87 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 357 | 85 |
| Methylprednisolone | Methylprednisolone | 347 | 236 |
| Ropinirole Hcl | Ropinirole Hcl | 344 | 86 |
| Famotidine | Famotidine | 338 | 89 |
| Duloxetine Hcl | Duloxetine Hcl | 334 | 77 |
| Temazepam | Temazepam | 332 | 56 |
| Tamsulosin Hcl | Tamsulosin Hcl | 330 | 90 |
| Ozempic | Semaglutide | 325 | 68 |
| Simvastatin | Simvastatin | 317 | 82 |
| Carvedilol | Carvedilol | 315 | 92 |
| Zolpidem Tartrate | Zolpidem Tartrate | 311 | 50 |
| Buspirone Hcl | Buspirone Hcl | 308 | 71 |
| Hydrochlorothiazide | Hydrochlorothiazide | 295 | 86 |
| Clopidogrel | Clopidogrel Bisulfate | 291 | 89 |
| Oxycodone Hcl | Oxycodone Hcl | 288 | 29 |
| Ondansetron Odt | Ondansetron | 286 | 98 |
| Glipizide | Glipizide | 275 | 68 |
| Metoprolol Tartrate | Metoprolol Tartrate | 268 | 68 |
| Levofloxacin | Levofloxacin | 249 | 166 |
| Eliquis | Apixaban | 246 | 57 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 245 | 65 |
| Celecoxib | Celecoxib | 238 | 77 |
| Citalopram Hbr | Citalopram Hydrobromide | 237 | 62 |
| Cefdinir | Cefdinir | 235 | 188 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 221 | 50 |
| Pioglitazone Hcl | Pioglitazone Hcl | 217 | 54 |
| Pravastatin Sodium | Pravastatin Sodium | 217 | 56 |
| Amoxicillin | Amoxicillin | 211 | 174 |
| Spironolactone | Spironolactone | 204 | 60 |
| Escitalopram Oxalate | Escitalopram Oxalate | 200 | 48 |
| Fluoxetine Hcl | Fluoxetine Hcl | 194 | 47 |
| Alendronate Sodium | Alendronate Sodium | 192 | 57 |
| Donepezil Hcl | Donepezil Hcl | 191 | 49 |
| Farxiga | Dapagliflozin Propanediol | 190 | 40 |
| Doxycycline Hyclate | Doxycycline Hyclate | 182 | 143 |
| Diazepam | Diazepam | 181 | 31 |
| Topiramate | Topiramate | 179 | 45 |
| Quetiapine Fumarate | Quetiapine Fumarate | 177 | 34 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 174 | 137 |
| Amitriptyline Hcl | Amitriptyline Hcl | 164 | 37 |
| Estradiol | Estradiol | 164 | 44 |
| Linzess | Linaclotide | 163 | 34 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 157 | 106 |
| Aripiprazole | Aripiprazole | 153 | 41 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 153 | 47 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 153 | 109 |
| Meclizine Hcl | Meclizine Hcl | 150 | 60 |
| Myrbetriq | Mirabegron | 150 | 34 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 148 | 43 |
| Doxepin Hcl | Doxepin Hcl | 147 | 38 |
| Allopurinol | Allopurinol | 144 | 36 |
| Jardiance | Empagliflozin | 144 | 33 |
| Bupropion Xl | Bupropion Hcl | 142 | 46 |
| Sucralfate | Sucralfate | 137 | 50 |
| Atenolol | Atenolol | 133 | 33 |
| Methocarbamol | Methocarbamol | 130 | 39 |
| Baclofen | Baclofen | 129 | 23 |
| Fluconazole | Fluconazole | 129 | 78 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 125 | 31 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 125 | 33 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 124 | 35 |
| Nystatin | Nystatin | 115 | 58 |
| Chlorthalidone | Chlorthalidone | 112 | 33 |
| Mupirocin | Mupirocin | 112 | 77 |
| Promethazine Hcl | Promethazine Hcl | 109 | 33 |
| Trulicity | Dulaglutide | 104 | 18 |
| Oxybutynin Chloride | Oxybutynin Chloride | 98 | 22 |
| Metformin Hcl Er | Metformin Hcl | 96 | 23 |
| Glimepiride | Glimepiride | 94 | 28 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 94 | 56 |
| Synthroid | Levothyroxine Sodium | 93 | 21 |
| Lansoprazole | Lansoprazole | 92 | 24 |
| Prednisone | Prednisone | 90 | 29 |
| Valacyclovir | Valacyclovir Hcl | 90 | 45 |
| Dicyclomine Hcl | Dicyclomine Hcl | 89 | 42 |
| Paroxetine Hcl | Paroxetine Hcl | 87 | 19 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 86 | 26 |
| Eszopiclone | Eszopiclone | 82 | 14 |
| Sumatriptan Succinate | Sumatriptan Succinate | 82 | 19 |
| Etodolac | Etodolac | 79 | 23 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 78 | 17 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 77 | 21 |
| Ezetimibe | Ezetimibe | 76 | 23 |
| Januvia | Sitagliptin Phosphate | 75 | 14 |
| Bumetanide | Bumetanide | 73 | 24 |
| Fenofibrate | Fenofibrate | 73 | 18 |
| Hydralazine Hcl | Hydralazine Hcl | 73 | 17 |
| Glipizide Er | Glipizide | 72 | 17 |
| Ibuprofen | Ibuprofen | 72 | 21 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 71 | 13 |
| Warfarin Sodium | Warfarin Sodium | 71 | 12 |
| Entresto | Sacubitril/Valsartan | 69 | 14 |
| Tresiba Flextouch U-100 | Insulin Degludec | 69 | 17 |
| Vraylar | Cariprazine Hcl | 69 | suppressed |
| Primidone | Primidone | 68 | 19 |
| Breo Ellipta | Fluticasone/Vilanterol | 66 | 15 |
| Ondansetron Hcl | Ondansetron Hcl | 66 | 27 |
| Propranolol Hcl | Propranolol Hcl | 63 | 16 |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 62 | 23 |
| Paxlovid | Nirmatrelvir/Ritonavir | 62 | 60 |
| Testosterone Cypionate | Testosterone Cypionate | 62 | 20 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 59 | 12 |
| Xarelto | Rivaroxaban | 59 | 13 |
| Cephalexin | Cephalexin | 57 | 43 |
| Tresiba Flextouch U-200 | Insulin Degludec | 57 | 11 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 56 | 13 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 56 | 41 |
| Levetiracetam | Levetiracetam | 55 | 11 |
| Olanzapine | Olanzapine | 55 | 12 |
| Mirtazapine | Mirtazapine | 54 | 20 |
| Nebivolol Hcl | Nebivolol Hcl | 54 | 15 |
| Terbinafine Hcl | Terbinafine Hcl | 54 | 23 |
| Symbicort | Budesonide/Formoterol Fumarate | 53 | 12 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 52 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 52 | 15 |
| Clonidine Hcl | Clonidine Hcl | 51 | 18 |
| Clindamycin Hcl | Clindamycin Hcl | 50 | 44 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 50 | 13 |
| Valsartan | Valsartan | 50 | 19 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 48 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 47 | 11 |
| Ramipril | Ramipril | 47 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 46 | 22 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 45 | 35 |
| Diclofenac Sodium Er | Diclofenac Sodium | 45 | 13 |
| Azithromycin | Azithromycin | 44 | 34 |
| Rybelsus | Semaglutide | 44 | 13 |
| Nitroglycerin | Nitroglycerin | 43 | 13 |
| Diltiazem Hcl | Diltiazem Hcl | 42 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 42 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 41 | suppressed |
| Clarithromycin | Clarithromycin | 40 | 30 |
| Colestipol Hcl | Colestipol Hcl | 40 | 15 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 40 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 40 | 16 |
| Propranolol Hcl Er | Propranolol Hcl | 40 | 12 |
| Lovastatin | Lovastatin | 39 | 12 |
| Memantine Hcl | Memantine Hcl | 39 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 38 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 37 | 12 |
| Gemfibrozil | Gemfibrozil | 36 | suppressed |
| Lamotrigine | Lamotrigine | 36 | 12 |
| Mometasone Furoate | Mometasone Furoate | 35 | 18 |
| Repatha Sureclick | Evolocumab | 35 | suppressed |
| Finasteride | Finasteride | 34 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 34 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 33 | 12 |
| Novolog Flexpen | Insulin Aspart | 33 | 11 |
| Benazepril Hcl | Benazepril Hcl | 32 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 32 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 31 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 31 | 11 |
| Oxcarbazepine | Oxcarbazepine | 30 | suppressed |
| Ssd | Silver Sulfadiazine | 30 | 19 |
| Torsemide | Torsemide | 30 | 13 |
| Carbamazepine | Carbamazepine | 29 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 29 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 29 | 14 |
| Flecainide Acetate | Flecainide Acetate | 28 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 28 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 28 | suppressed |
| Metronidazole | Metronidazole | 28 | 19 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 28 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 27 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 27 | suppressed |
| Phenobarbital | Phenobarbital | 27 | suppressed |
| Naproxen | Naproxen | 26 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 26 | 25 |
| Rizatriptan | Rizatriptan Benzoate | 26 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 25 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 25 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 24 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 24 | suppressed |
| Dutasteride | Dutasteride | 24 | suppressed |
| Febuxostat | Febuxostat | 24 | suppressed |
| Naloxone Hcl | Naloxone Hcl | 24 | 22 |
| Sotalol | Sotalol Hcl | 24 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 23 | suppressed |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 23 | suppressed |
| Hydrocortisone | Hydrocortisone | 23 | suppressed |
| Klor-Con M20 | Potassium Chloride | 23 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 23 | suppressed |
| Prolia | Denosumab | 23 | 20 |
| Telmisartan | Telmisartan | 23 | suppressed |
| Lactulose | Lactulose | 22 | suppressed |
| Ranolazine Er | Ranolazine | 22 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 21 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 21 | suppressed |
| Tradjenta | Linagliptin | 21 | suppressed |
| Zaleplon | Zaleplon | 21 | suppressed |
| Armodafinil | Armodafinil | 20 | suppressed |
| Colchicine | Colchicine | 20 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 20 | suppressed |
| Nifedipine Er | Nifedipine | 20 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 20 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 19 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 19 | 18 |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 19 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 18 | suppressed |
| Insulin Syringe | Syring-Needl,disp,insul,0.3 Ml | 18 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 18 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 17 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 17 | suppressed |
| Lubiprostone | Lubiprostone | 17 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 16 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Dextroamphetamine Sulfate Er | Dextroamphetamine Sulfate | 16 | suppressed |
| Lacosamide | Lacosamide | 16 | suppressed |
| Lidocaine | Lidocaine | 16 | suppressed |
| Mitigare | Colchicine | 16 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 16 | suppressed |
| Calcitriol | Calcitriol | 15 | suppressed |
| Captopril | Captopril | 15 | suppressed |
| Constulose | Lactulose | 15 | 11 |
| Fenofibrate | Fenofibrate,micronized | 15 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 15 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 15 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Cilostazol | Cilostazol | 14 | suppressed |
| Creon | Lipase/Protease/Amylase | 14 | suppressed |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 14 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 14 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 14 | suppressed |
| Zonisamide | Zonisamide | 14 | suppressed |
| Carisoprodol | Carisoprodol | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 13 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 13 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Rivastigmine | Rivastigmine | 13 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 12 | suppressed |
| Amiloride-Hydrochlorothiazide | Amiloride/Hydrochlorothiazide | 12 | suppressed |
| Digoxin | Digoxin | 12 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 12 | suppressed |
| Indomethacin | Indomethacin | 12 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 12 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 12 | suppressed |
| Oxymorphone Hcl Er | Oxymorphone Hcl | 12 | suppressed |
| Premarin | Estrogens, Conjugated | 12 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 12 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 12 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 12 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 12 | suppressed |
| Triazolam | Triazolam | 12 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Clotrimazole | Clotrimazole | 11 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 11 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 11 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 11 | suppressed |
| Latanoprost | Latanoprost | 11 | suppressed |
| Levemir Flexpen | Insulin Detemir | 11 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 11 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $854.19 · 44 records | Novo Nordisk Inc | Auvelity, BREZTRI, CAPLYTA, Cologuard Collection Kit, ELIQUIS, EVENITY, FANAPT, FREESTYLE LIBRE 3, GEMTESA, General - Pain Management, IBSRELA, JARDIANCE, Kerendia, Korlym, MOUNJARO, NURTEC ODT, Ohtuvayre, Ozempic, Rybelsus, Wegovy, XIFAXAN, ZAVZPRET | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Amgen Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error